Dyspepsia Clinical Trial
— MEASuRE-DOfficial title:
The Experience Sampling Method (ESM): Validation of a Newly Developed Real-time Patient-Reported Outcome Measure (PROM) and Its Evaluation of Triggers for Functional Dyspepsia
Verified date | October 2020 |
Source | Maastricht University Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Background:
Reliable patient reported outcome measures (PROM's) for symptom assessment in functional
dyspepsia (FD) are essential in order to evaluate dyspeptic symptoms, identify potential
symptom triggers and optimize therapeutic strategies, since biological markers are
unavailable. Currently used symptom assessment methods, i.e. end-of-day or end-of-week
questionnaires, have considerable limitations. The Experience Sampling Method (ESM), an
electronic questioning method characterized by random and repeated, momentary assessments in
the subject's current state and environment, might overcome these limitations. The aim of
this study is to assess the validity and reliability of an FD-specific electronic
patient-reported outcome measure (ePRO), based on the Experience Sampling Method-principle,
for symptom assessment and identification of symptom triggers in patients with functional
dyspepsia.
Objective:
The aim of this study is to assess the validity and reliability of an FD-specific electronic
patient-reported outcome measure (ePRO), based on the Experience Sampling Method-principle,
for symptom assessment and identification of symptom triggers in patients with functional
dyspepsia. In order to measure this, internal consistency, test-retest reliability,
concurrent validity and the accuracy to differentiate between dyspeptic patients and healthy
controls of the developed ePRO will be assessed. In addition, to objectify specific triggers
for the onset of gastrointestinal symptoms in dyspepsia, using the FD-specific ESM tool.
Status | Completed |
Enrollment | 72 |
Est. completion date | October 1, 2020 |
Est. primary completion date | October 1, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Both patients with functional dyspepsia (36) as healthy controls (36) will be included Inclusion Criteria for patients with functional dyspepsia: • A diagnosis of functional dyspepsia according to ROME IV criteria (2): - One or more of the following: - Bothersome postprandial fullness - Bothersome early satiation - Bothersome epigastric pain - Bothersome epigastric burning AND - No evidence of structural disease (confirmed by upper endoscopy) that is likely to explain the symptoms. - Criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis. - Age between 18 and 75 years; - Ability to understand and speak the Dutch language; - Ability to understand how to utilize the ESM tool. Inclusion criteria for healthy volunteers: - Age between 18 and 75 years - Ability to understand and speak the Dutch language - Ability to understand how to utilize the ESM tool. Exclusion Criteria for patients with functional dyspepsia: - Any organic explanation for the gastrointestinal complaints; - Initiation of regularly used medication from one month before inclusion until the end of study participation; - A history of upper digestive surgery influencing end points - A history of radiation therapy of the abdomen - Pregnancy Exclusion Criteria for healthy controls: - Current diagnosis of any gastrointestinal disorder - Current gastrointestinal symptoms suiting the ROME IV criteria for FD - Initiation of regularly used medication from one month before inclusion until the end of study participation - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Netherlands | Maastricht University Medical Center | Maastricht | Limburg |
Lead Sponsor | Collaborator |
---|---|
Maastricht University Medical Center |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in experience sampling method (ESM) scores | Using the MEASuRE-D app, the same ESM questionnaire will be filled in 10 times per day at random intervals. This results in a lot of real-time data on patient symptom scores on which changes over the course of the day can be seen. | 10 times daily, during 1 week | |
Primary | Patient complaint diary | Using the MEASuRE-D app, patients will fill out a complaints diary at the end of each day during 7 days | End of day 1, end of day 2, end of day 3, end of day 4, end of day 5, end of day 6, end of day 7 | |
Secondary | Questionnaire for demographic characteristics | A questionnaire for demographic characteristics will be filled in by participants. | On day 7 | |
Secondary | PAGI-SYM questionnaire | the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity index (PAGI-SYM) questionnaire will be filled in by participants. Questions about upper gastrointestinal symptoms are asked on a 6 point likert scale with 0 indicating not at all and 5 indicating very severe. | On day 7 | |
Secondary | NDI questionnaire | The Nepean Dyspepsia Index (NDI) questionnaire will be filled in by participants. The NDI questionaire consists of various questions. Questions about the effects of upper gastrointestinal symptoms are asked on a 5 point likert scale with 1 indicating not at all/almost never and 5 indicating very severe/always. |
On day 7 | |
Secondary | GSRS questionnaire | The Gastrointestinal Symptom Rating Scale (GSRS) will be filled in by participants. Questions about gastrointestinal symptoms are asked on a 7 point likert scale with 0 indicating not at all and 6 indicating very severe. | On day 7 | |
Secondary | PHQ-9 questionnaire | The Patient Health Questionnaire-9 (PHQ-9) will be filled in by participants. Questions about the severity of depressive symptoms are asked on a scale from 0 - 3, where 0 indicates not at all, 1 indicates some days, 2 indicates more than half of the days, and 3 indicates almost every day. | On day 7 | |
Secondary | GAD-7 questionnaire | The Generalized Anxiety Disorder-7 (GAD-7) questionnaire will be filled in by participants. Questions about the severity of anxiety symptoms are asked on a scale from 0 - 3, where 0 indicates not at all, 1 indicates some days, 2 indicates more than half of the days, and 3 indicates almost every day. | On day 7 | |
Secondary | PHQ-15 questionnaire | The Patient Health Questionnaire-15 (PHQ-15) will be filled in by participants. Questions about somatization symptoms are asked in the following matter: how often have you been bothered by "..." on a scale from 0 - 2, where 0 indicates not at all, 1 indicates bothered a little, and 2 indicates bothered a lot. | On day 7 | |
Secondary | SF-36 questionnaire | The Short Form-36 (SF-36) questionnaire will be filled in by participants and consits of various types of questions. Some questions about how their health limits them in certain daily activities are asked on a scale of 1-3, with 1 indicating limits severely, 2 indicating limits a little, and 3 indicating not limited at all Some questions about problems in participants' work or daily activities due to physical health, emotional problems are dichotomous with 1 indicating yes and 2 indicating no Some questions about how participants felt themselves during a period are asked on a 6 point scale with 1 indicating all the time, 2 indicating most of the time, 3 indicating often, 4 indicating sometimes, 5 indicating occasionally, and 6 indicating not at all Participants need to indicate how much a few statements apply to them with 1 indicating completely correct, 2 indicating mostly correct, 3 indicating I don't know, 4 indicating mostly incorrect, and 5 indicating completely correct |
On day 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06094062 -
Smartphone App-assisted PPI
|
N/A | |
Completed |
NCT03941288 -
Efficacy and Safety of Cannabidiol for Gastroparesis and Functional Dyspepsia
|
Phase 2 | |
Completed |
NCT04429802 -
The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Withdrawn |
NCT02863822 -
Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.
|
N/A | |
Recruiting |
NCT00978159 -
Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
|
Phase 4 | |
Completed |
NCT00723502 -
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
|
Phase 2 | |
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00148603 -
Montelukast in the Treatment of Duodenal Eosinophilia
|
N/A | |
Terminated |
NCT00220844 -
Tricyclic Antidepressants (TCAs) on Gastric Emptying
|
N/A | |
Completed |
NCT00232102 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Completed |
NCT00232037 -
Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia
|
Phase 3 | |
Completed |
NCT00164996 -
Ultrathin Versus Conventional Esophagogastroduodenoscopy in Unsedated Patient With or Without Local Pharyngeal Anaesthesia
|
Phase 3 | |
Completed |
NCT00110968 -
Long-term Safety and Efficacy of Itopride Hydrochloride (HCl) in Patients Suffering From Functional Dyspepsia
|
Phase 3 | |
Recruiting |
NCT05718960 -
Traditional Dietary Advice Versus Reassurance-alone in Postprandial Functional Dyspepsia
|
N/A | |
Terminated |
NCT04247100 -
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
|
N/A | |
Completed |
NCT05750641 -
The Efficacy of Removal of Animal Milk From the Diet in Functional Dyspepsia: A Cross-sectional Study
|
||
Completed |
NCT03252743 -
ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.
|
N/A | |
Completed |
NCT04697641 -
Helicobacter Pylori Eradication in Functional Dyspepsia
|
N/A | |
Recruiting |
NCT04918329 -
Functional Digestive Disorders Observatory
|